SEC Form 4 · accession 0001567619-18-001186
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Georgiou
Director
Period of report
Aug 13, 2018
Accepted (ET)
Aug 15, 2018 · 4:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 13, 2018 | M | 17,333 | $7.28 | A | 155,861 | D | |
| Common Stock | Aug 13, 2018 | M | 20,000 | $4.73 | A | 175,861 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F1 | $7.28 | Aug 13, 2018 | M | 17,333 | D | — | May 16, 2026 | Common Stock | 17,333 | 6,667 | D |
| Director Stock Option (right to buy)F2 | $4.73 | Aug 13, 2018 | M | 20,000 | D | — | Nov 30, 2027 | Common Stock | 20,000 | 10,000 | D |
Explanation of responses
- F1The stock option vested and became exercisable, and shall continue to vest and become exercisable, in 36 equal monthly installments beginning on June 17, 2016, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
- F2The stock option vested and became exercisable, and shall continue to vest and become exercisable, in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.